Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928132 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1USP2POLBLMNA | |
| SCHEMBL2951425 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1USP2POLBLMNA | |
| Fluoride SCHEMBL28073285 | 0.97 | KDM4E (0.56) | KDM4EALDH1A1USP2POLBLMNA | |
| SCHEMBL3339822 | 0.97 | KDM4E (0.60) | KDM4EALDH1A1USP2POLBLMNA | |
| SCHEMBL18228600 | 0.97 | KDM4E (0.60) | KDM4EALDH1A1USP2POLBLMNA | |
| SCHEMBL2168776 | 0.92 | KDM4E (0.60) | KDM4EALDH1A1USP2POLBLMNA | |
| SCHEMBL14503198 | 0.91 | MEN1 (0.56) | KDM4EALDH1A1USP2POLBLMNA | |
| Water SCHEMBL28082091 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1USP2POLBLMNA | |
| Ammonia Solution, Strong SCHEMBL28080150 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1USP2POLBLMNA | |
| Piperazine SCHEMBL28070940 | 0.89 | ALDH1A1 (0.70) | KDM4EALDH1A1USP2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| CN-114588158-A | Application of indole piperidine pyrimidine derivatives in preparation of novel coronavirus inhibitor | 武汉工程大学 | 2022-06-07 | — | — | CN | claimed |
| CN-114539246-A | Piperidinopyrimidine compound and application thereof | 苏州闻天医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114507218-A | Indole piperidine pyrimidine derivatives, and preparation method and application thereof | 武汉工程大学 | 2022-05-17 | — | — | CN | claimed |
| CN-113164618-A | Methods and compositions for treating diseases with immunostimulatory conjugates | 希沃尔拜克治疗公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3849615-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | Silverback Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | SILVERBACK THERAPEUTICS, INC. (US) | 2020-04-16 | — | — | US | claimed |
| WO-2020056008-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | claimed |
| US-20050037060-A1 | Pharmaceutical composition | CONNETICS CORPORATION (US) | 2005-02-17 | — | — | US | claimed |
| EP-0951280-B1 | HYDROPHILIC MICROPARTICLES AND METHODS TO PREPARE SAME | HERMES BIOSCIENCES INC (US) | 2004-01-14 | — | — | EP | claimed |
| EP-1369111-A1 | Hydrophilic microparticles and methods to prepare same | Hermes Biosciences, Inc. (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1073439-A4 | PHARMACEUTICAL COMPOSITION | CONNETICS AUSTRALIA PTY LTD (AU) | 2003-07-02 | — | — | EP | claimed |
| EP-0892795-B1 | PIPERIDINYLPYRAMIDINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2003-01-08 | — | — | EP | claimed |
| US-20020172649-A1 | Pharmaceutical composition | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2002-11-21 | — | — | US | claimed |
| EP-1073439-A1 | PHARMACEUTICAL COMPOSITION | SOLTEC RESEARCH PTY. LTD. (AU) | 2001-02-07 | — | — | EP | claimed |
| EP-1025091-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE OR NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Krenitsky Pharmaceuticals, Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999053923-A1 | PHARMACEUTICAL COMPOSITION | SOLTEC RESEARCH PTY. LTD. (AU) | 1999-10-28 | — | — | WO | claimed |
| WO-1999019305-A2 | SUBSTITUTED PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE OR NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM | KRENITSKY PHARMACEUTICALS INC. (US) | 1999-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113912-A1 | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates | CD74, CD47, CD69 | KDM4E 4500/4885ALDH1A1 1343/4885USP2 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.